{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G100",
    "query": {
      "intervention": "G100"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G100&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T09:06:30.210Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02387125",
      "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "CMB305",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Metronomic CPA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 79,
      "start_date": "2015-02-28",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 8,
      "location_summary": "Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02387125"
    },
    {
      "nct_id": "NCT07282886",
      "title": "VENTURI (VENTilation Using Respiratory Imaging)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-03-15",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282886"
    },
    {
      "nct_id": "NCT02353013",
      "title": "Effect of Protein Intake on Preterm Infant Body Composition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Premature; Infant, Light-for-dates"
      ],
      "interventions": [
        {
          "name": "Protein supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard fortification",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "1 Minute to 1 Year"
      },
      "enrollment_count": 36,
      "start_date": "2014-12",
      "completion_date": "2017-10-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02353013"
    },
    {
      "nct_id": "NCT00493311",
      "title": "Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fever"
      ],
      "interventions": [
        {
          "name": "IV Placebo",
          "type": "DRUG"
        },
        {
          "name": "IV Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Reference Standard Endotoxin (RSE)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2007-06",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00493311"
    },
    {
      "nct_id": "NCT00504075",
      "title": "A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Gammaplex, intravenous immunoglobulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bio Products Laboratory",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2007-09",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-01",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 7,
      "location_summary": "Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504075"
    },
    {
      "nct_id": "NCT02145949",
      "title": "Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Atrophy",
        "Quality of Life"
      ],
      "interventions": [
        {
          "name": "Essential Amino Acids (EAA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Alanine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oregon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-12",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 2,
      "location_summary": "Eugene, Oregon",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145949"
    },
    {
      "nct_id": "NCT01866943",
      "title": "Role of Topical Tranexamic Acid in Total Hip Arthroplasty",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Operative Blood Loss"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2011-11",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01866943"
    },
    {
      "nct_id": "NCT05309304",
      "title": "Cefazolin PK Study 3g vs 2g",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxter Healthcare Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-02-14",
      "completion_date": "2022-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309304"
    },
    {
      "nct_id": "NCT04156464",
      "title": "Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcohol Withdrawal",
        "Alcohol Withdrawal Delirium"
      ],
      "interventions": [
        {
          "name": "Phenobarbital",
          "type": "DRUG"
        },
        {
          "name": "Lorazepam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OSF Healthcare System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2020-07-06",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 1,
      "location_summary": "Peoria, Illinois",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04156464"
    },
    {
      "nct_id": "NCT00399568",
      "title": "Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain",
        "Hysterectomy"
      ],
      "interventions": [
        {
          "name": "IV Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo 100 mL solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 331,
      "start_date": "2006-11",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-21",
      "last_synced_at": "2026-09-07T09:06:30.210Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00399568"
    }
  ]
}